EW Investors Have Opportunity to Lead Edwards Lifesciences Corporation Securities Fraud Lawsuit
Investors who have been following Edwards Lifesciences Corporation have an opportunity to get involved in a securities fraud lawsuit. The Rosen Law Firm is reminding those who purchased securities of Edwards Lifesciences Corporation (NYSE: EW) between February 6, 2024, and July 24, 2024, about the upcoming lead plaintiff deadline on December 13, 2024.
If you bought Edwards securities during this time, you may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement. To join the class action lawsuit, visit the Rosen Law Firm website or reach out to Phillip Kim, Esq. at 866-767-3653 or via email for more information. A class action lawsuit has already been filed, so if you want to be the lead plaintiff, make sure to take action by December 13, 2024.
Rosen Law Firm is known for representing investors globally in securities class actions and shareholder derivative litigation. With a track record of success, they have achieved substantial settlements for investors over the years. In this particular case, the lawsuit alleges that during the Class Period, there were misleading statements made about Edwards’ expected revenue for the fiscal year 2024, especially related to the growth of their core product, Transcatheter Aortic Valve Replacement (“TAVR”).
For more details on how to participate in the lawsuit or to stay updated on this case, visit the Rosen Law Firm website or contact Phillip Kim, Esq. at 866-767-3653. Remember, no class has been certified yet, so it’s important to stay informed and take the necessary steps if you wish to be involved in seeking potential recovery.
Stay connected with us on LinkedIn for any further updates.
